Stryker Corp Stock Price, News & Analysis

Stryker (NYSE:SYK) has received FDA 510(k) clearance for its Incompass® Total Ankle System, designed for patients with severe ankle joint conditions. The system integrates technologies from Stryker's Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement.

The innovative platform incorporates Adaptis® Boney Ingrowth Technology and is informed by data from over 85,000 CT scans and 100,000 clinical cases. Built using the SOMA platform and Prophecy Surgical Planning System, Incompass features redesigned instrumentation, improved alignment systems, and streamlined surgical workflow to enhance procedural efficiency and patient-specific care.

Stryker (NYSE:SYK) has received FDA 510(k) clearance for its OptaBlate basivertebral nerve ablation system (OptaBlate BVN), designed to treat chronic vertebrogenic low back pain. The system represents a minimally invasive solution that targets the basivertebral nerve for long-lasting pain relief. Key features include achieving a 1 cm lesion in 7 minutes, steerable curved introducer, microinfusion technology for hydration, and 10-gauge access tools. This addition expands Stryker's pain management portfolio, combining their expertise in radiofrequency ablation technology and vertebral access. The system will be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, FL, July 17-20.

Stryker (NYSE:SYK) has announced its quarterly dividend declaration of $0.84 per share. The dividend will be payable on July 31, 2025, to shareholders of record as of June 30, 2025. This dividend amount represents a 5.0% increase compared to the previous year while remaining unchanged from the last quarter's distribution.

Stryker (NYSE:SYK) reported strong Q1 2025 results with reported net sales increasing 11.9% to $5.9 billion and organic net sales growth of 10.1%. The company's MedSurg and Neurotechnology segment saw net sales rise 13.4% to $3.5 billion, while Orthopaedics net sales grew 9.7% to $2.4 billion. Despite reported EPS decreasing 17.6% to $1.69, adjusted EPS increased 13.6% to $2.84. The company raised its full-year 2025 organic net sales growth guidance to 8.5-9.5% and updated adjusted EPS guidance to $13.20-$13.45, accounting for the Inari Medical acquisition dilution and a $200 million tariff impact.

Stryker (NYSE:SYK) has announced its participation in the upcoming Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada.

Key details:

• Presenters: Preston Wells (Vice President and Chief Financial Officer) and Jason Beach (Vice President, Finance and Investor Relations)
• Presentation Time: 1:40 p.m. Pacific Time
• Access: Live webcast and replay available on www.stryker.com
• Availability: Recording will be archived on the Investor Relations page

Stryker (NYSE:SYK) has scheduled its first quarter fiscal year 2025 financial results announcement for Thursday, May 1, 2025. The company will release a press release containing summary financial information at approximately 4:05 p.m. ET, covering the quarter ending March 31, 2025.

A webcast to discuss the Q1 2025 results will be held at 4:30 p.m. ET on the same day. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available on the company's website two hours after the live call concludes.

Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, , which will operate under the newly formed VB Spine, . The strategic divestment aims to enhance Stryker's focus and enable investments in areas with greater innovation and growth potential.

As part of the agreement, VB Spine will have exclusive access to Mako Spine and Copilot technologies for spine procedures. Stryker maintains its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, along with a strategic partnership with VB Spine.

The transaction's international component will be executed in phases, with transfers to VB Spine in certain markets pending legal, regulatory, and employee consultation requirements.

Stryker (NYSE:SYK) has nominated Emmanuel "Manny" Maceda to its board of directors, with the election scheduled for the Annual Meeting of Shareholders on May 8, 2025. Maceda brings over 30 years of experience in leading organizations and advising executives on corporate transformations.

Maceda currently serves as Chairman of Bain & Company, following his role as Worldwide Managing Partner and CEO from 2018 to 2024. During his leadership, he drove Bain's global transformation across 50+ offices, strengthening digital capabilities and expanding sustainability focus. Since joining Bain in 1989, he has held various senior leadership positions and advised CEOs on strategy, growth, and organizational effectiveness.

Stryker (NYSE:SYK) has scheduled its 2025 Annual Meeting of Shareholders for Thursday, May 8, 2025, at 9:30 a.m. Eastern Time. The meeting will be conducted virtually via the internet.

Shareholders can access the webcast, including audio and slide presentation, through the company's Investor Relations page at www.investorevents.stryker.com. For audio-only participation, attendees can dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Annual Meeting."

A recording will be available from 10:30 a.m. ET on May 9, 2025, at www.virtualshareholdermeeting.com/SYK2025 until the 2026 proxy statement filing.